Campath, Chemo and/or TBI Allo SCT ( DrugBank: - )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
60	Aplastic anemia	1
62	Paroxysmal nocturnal hemoglobinuria	1
283	Acquired pure red cell aplasia	1

60. Aplastic anemia

---

Clinical trials : 235 /  Drugs : 381 - (DrugBank : 83) / Drug target genes : 44 - Drug target pathways : 160

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004143 (ClinicalTrials.gov)	September 1999	10/12/1999	Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes	Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes	Sickle Cell Anemia;Severe Aplastic Anemia;Paroxysmal Nocturnal Hemoglobinuria (PNH);Pure Red Cell Aplasia	Drug: Campath, Chemo and/or TBI Allo SCT	David Rizzieri, MD	NULL	Completed	18 Years	N/A	All	2	Phase 2	United States

62. Paroxysmal nocturnal hemoglobinuria

---

Clinical trials : 271 /  Drugs : 163 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 106

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004143 (ClinicalTrials.gov)	September 1999	10/12/1999	Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes	Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes	Sickle Cell Anemia;Severe Aplastic Anemia;Paroxysmal Nocturnal Hemoglobinuria (PNH);Pure Red Cell Aplasia	Drug: Campath, Chemo and/or TBI Allo SCT	David Rizzieri, MD	NULL	Completed	18 Years	N/A	All	2	Phase 2	United States

283. Acquired pure red cell aplasia

---

Clinical trials : 18 /  Drugs : 42 - (DrugBank : 22) / Drug target genes : 19 - Drug target pathways : 98

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004143 (ClinicalTrials.gov)	September 1999	10/12/1999	Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes	Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes	Sickle Cell Anemia;Severe Aplastic Anemia;Paroxysmal Nocturnal Hemoglobinuria (PNH);Pure Red Cell Aplasia	Drug: Campath, Chemo and/or TBI Allo SCT	David Rizzieri, MD	NULL	Completed	18 Years	N/A	All	2	Phase 2	United States